Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
暂无分享,去创建一个
[1] A. Hart,et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment , 2021, Alimentary pharmacology & therapeutics.
[2] S. Ng,et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease , 2021, Nature Reviews Gastroenterology & Hepatology.
[3] T. Pietrzykowski,et al. The reality of informed consent: empirical studies on patient comprehension—systematic review , 2021, Trials.
[4] G. Rogler,et al. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program , 2020, Inflammatory bowel diseases.
[5] B. Sands,et al. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] B. Sands,et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme , 2019, Alimentary pharmacology & therapeutics.
[7] H. Yazici,et al. Informed consent: time for more transparency , 2010, Arthritis research & therapy.
[8] A. Iliadou,et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[9] E. Zintzaras,et al. The risk of lymphoma development in autoimmune diseases: a meta-analysis. , 2005, Archives of internal medicine.
[10] C. Brensinger,et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. , 2001, Gastroenterology.
[11] Daryl E. Chubin,et al. Open Science and Closed Science: Tradeoffs in a Democracy , 1985 .